Embecta Corp. (EMBC) Stock Price, Financials & Summary

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$6.32

From 52W high−57.58%

Volume899639.00

Market cap$351.86M

P/E (TTM)4.2x

P/S (TTM)0.3x

Div yield5.15%

Key dataOct 19, 2026

Open

$6.32

From 52W high

−57.58%

Volume

899639.00

Market cap

$351.86M

ValuationView details →

P/E (Fwd)

3.4x

EV/EBITDA

6.2x

P/E (TTM)

4.2x

RSI (14)

62.6

MomentumView details →

1D Return

−0.96%

YTD Return

−47.55%

SummaryUpdated Jun 1, 2026

Embecta Corp. (NASDAQ:EMBC) is a medical device company that specializes in diabetes care solutions, operating as the world's largest dedicated diabetes injection device manufacturer. Founded in 1924 as part of Becton, Dickinson and Company (BD), Embecta became an independent public company in April 2022 following a spin-off from its former parent. The company is headquartered in Parsippany, New Jersey, and serves diabetes patients globally through a comprehensive portfolio of injection devices and related products. Since its independence, Embecta has focused on strengthening its core diabetes injection business while exploring new growth opportunities in the evolving diabetes care market.

Ask drillr about Embecta Corp. →

ValuationView details →

P/E (Fwd)

3.4x

P/E (TTM)

4.2x

EV/EBITDA

6.2x

EV/Sales

1.6x

P/S (TTM)

0.3x

P/B (TTM)

−0.6x

ProfitabilityView details →

Gross Margin

59.89%

Net Margin

8.59%

EBITDA Margin

26.10%

ROE (TTM)

−14.28%

ROA (TTM)

6.92%

Asset Turnover

0.89x

GrowthView details →

Revenue YoY

−7.60%

EPS YoY

+5.08%

FCF YoY

+24.41%

Revenue CAGR 3Y

−1.47%

EPS CAGR 3Y

−25.21%

EBITDA YoY

+3.10%

MomentumView details →

1D Return

−0.96%

YTD Return

−47.55%

1Y Return

−55.80%

RSI (14)

62.6

vs 50D SMA

+13.94%

vs 200D SMA

−6.99%

Capital & dividendView details →

Debt/Equity

−2.45x

Current Ratio

1.68x

Quick Ratio

1.68x

Div Yield

5.15%

Div Rate

$0.32

Div Growth 1Y

+0.00%

EarningsView details →

EPS (Actual)

$0.56

EPS Surprise

110.68%

Beats (12Q)

10/12

Next Q EPS Est

$0.49

Avg Surprise (4Q)

12.78%

Rev Surprise

6.10%

Financials snapshotView financials →

Revenue (TTM)

1.02B

Net Income (TTM)

87.50M

Op. CF (TTM)

174.10M

Next earningsNov 24, 2026 →

Latest newsMore news →

Bernstein Liebhard LLP announced an investigation into potential breaches of fiduciary duty by directors and officers of Embecta Corp.54d ago

A class action lawsuit was filed against Embecta Corp. on behalf of investors who purchased Embecta securities between November 25, 2025 and May 4, 2026.68d ago

Similar companies

Alpha Teknova, Inc.TKNO Emergent BioSolutions Inc.EBS SNDL Inc.SNDL Canopy Growth CorporationCGC Wai Yuen Tong Medicine Holdings Limited00897.HK Kamada Ltd.KMDA Find similar companies →

Latest newsMore news →

Bernstein Liebhard LLP announced an investigation into potential breaches of fiduciary duty by directors and officers of Embecta Corp.54d ago A class action lawsuit was filed against Embecta Corp. on behalf of investors who purchased Embecta securities between November 25, 2025 and May 4, 2026.68d ago Pomerantz LLP announced that a class action lawsuit has been filed against Embecta Corp. alleging securities fraud or other unlawful business practices by the company and certain officers and/or directors.72d ago